长期接受利妥昔单抗治疗的类风湿关节炎患者是否应维持完全B细胞清除?
该回顾性研究纳入2019至2021年间接受利妥昔单抗维持治疗的126例类风湿关节炎患者,比较持续完全B细胞清除者与未持续完全清除者四次输注访视时的平均DAS28-CRP,发现两组主要及次要结局均无显著差异,结论认为维持完全B细胞清除似乎不是长期利妥昔单抗治疗中应追求的治疗目标。
要点
- 126例长期利妥昔单抗维持治疗的类风湿关节炎患者中,43例(34%)在最后四次输注时均维持完全B细胞清除。
- 持续完全B细胞清除组与未持续完全清除组在四次访视的平均DAS28-CRP无显著差异,调整抗体状态、既往治疗数、输注次数和累积剂量后结果不变。
- 所有次要结局在两组间亦无显著差异,提示在已获低疾病活动度/缓解的长期利妥昔单抗治疗患者中监测CD19获益有限。
核心结论
- 维持完全B细胞清除似乎不是长期利妥昔单抗维持治疗的类风湿关节炎患者应追求的治疗目标。
- 在已获低疾病活动度/缓解的长期利妥昔单抗治疗类风湿关节炎患者中,监测CD19的获益有限。
研究设计与样本
- 回顾性研究,纳入2019至2021年间因新一次输注就诊的类风湿关节炎患者126例,均在接受利妥昔单抗维持治疗。
- 暴露期76(5)个月,接受14(7)次输注;持续完全B细胞清除定义为最后四次访视每次平均CD19计数<18/µl。
主要发现
- 126例中43例(34%)在最后四次输注时均维持持续完全B细胞清除。
- 持续完全B细胞清除组与未持续完全清除组在最后四次输注访视时计算的平均DAS28-CRP无显著差异。
- 调整抗体状态、既往治疗数、利妥昔单抗输注次数和累积利妥昔单抗剂量后,DAS28-CRP结果不变。
- 所有次要结局(DAS28、疼痛/疲劳视觉模拟量表、CRP、γ球蛋白及自报类风湿关节炎发作频率)在两组间亦无显著差异。
关键数值与推荐
- 持续完全B细胞清除定义为最后四次访视每次平均CD19计数<18/µl;未持续完全清除定义为最后四次访视平均CD19计数≥18/µl。
- 主要终点为比较两组在最后四次输注访视时计算的平均DAS28-CRP。
临床怎么用
- 原文结论认为维持完全B细胞清除似乎不是长期利妥昔单抗治疗类风湿关节炎患者应追求的治疗目标。
- 原文结论认为在已获低疾病活动度/缓解的长期利妥昔单抗治疗类风湿关节炎患者中监测CD19获益有限。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether persistent complete B cell (BC) depletion was associated with a better clinical response in rheumatoid arthritis (RA) patients long-term treated with rituximab (RTX). METHODS: We conducted a retrospective study including RA patients admitted for a new infusion between 2019 and 2021. The primary endpoint was the comparison of the mean disease activity score based on 28 joints (DAS28)-CRP at each of the four last infusion visits between patients with persistent complete BC depletion (mean CD19 counts <18/µl at each of the last four visits) or without persistent complete BC depletion (mean CD19 counts of the last four visits ≥18/µl). Secondary endpoints included DAS28, pain/fatigue visual analogue scale, CRP, gammaglobulins and the frequency of self-reported RA flares. RESULTS: Of the 126 patients in maintenance therapy with RTX [exposure period: 76 (5) months, 14 (7) infusions received], 43 (34%) had persistent complete BC depletion at each of the four last infusions. The mean DAS28-CRP calculated at each of the four last infusion visits did not significantly differ according to persistence or not of complete BC depletion. This result remained unchanged after adjusting for antibody status, number of previous therapies, number of RTX infusion and cumulative RTX dose. All secondary outcomes were also not significantly different between the two groups. CONCLUSION: Maintaining complete BC depletion does not appear to be a therapeutic target to achieve in RA patients in long-term maintenance therapy with RTX. There is a limited benefit of monitoring CD19 in RA patients long-term treated with RTX and having achieved low disease activity/remission.
引用
- Ghossan R, Al Tabaa O, Combier A, et al. Should complete B cell depletion be maintained in patients treated long-term with rituximab for rheumatoid arthritis? Rheumatology (Oxford). 2024. PMID: 37792482. doi:10.1093/rheumatology/kead528
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。